Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.
Identifieur interne : 002D79 ( Main/Exploration ); précédent : 002D78; suivant : 002D80Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.
Auteurs : RBID : pubmed:15869458English descriptors
- KwdEn :
- Adult, Aged, DNA (metabolism), Female, Humans, Indium (pharmacology), Indium Radioisotopes (pharmacology), Liver (pathology), Liver Neoplasms (secondary), Liver Neoplasms (therapy), Magnetic Resonance Imaging, Male, Microscopy, Electron, Middle Aged, Neoplasm Metastasis (pathology), Neoplasms (pathology), Neuroendocrine Tumors (radiotherapy), Octreotide (analogs & derivatives), Octreotide (pharmacology), Pentetic Acid (analogs & derivatives), Pentetic Acid (pharmacology), Radionuclide Imaging, Tomography, X-Ray Computed, Ultrasonics, Ultrasonography.
- MESH :
- chemical , analogs & derivatives : Octreotide, Pentetic Acid.
- chemical , metabolism : DNA.
- chemical , pharmacology : Indium, Indium Radioisotopes, Octreotide, Pentetic Acid.
- pathology : Liver, Neoplasm Metastasis, Neoplasms.
- radiotherapy : Neuroendocrine Tumors.
- secondary : Liver Neoplasms.
- therapy : Liver Neoplasms.
- Adult, Aged, Female, Humans, Magnetic Resonance Imaging, Male, Microscopy, Electron, Middle Aged, Radionuclide Imaging, Tomography, X-Ray Computed, Ultrasonics, Ultrasonography.
Abstract
Thirteen (13) patients with liver neuroendocrine carcinomas metastases, positive for somatostatin receptors, confirmed by scintigraphy were infused with 4070-7030 MBq per session of In-111-octreotide after selective hepatic catheterization, exploiting the catastrophic activity of Indium Auger and Internal Conversion electron emission on cell DNA. Evaluation of the treatment was assessed by ultrasonography (US) as well as by computed tomography and/or magnetic resonance imaging scans. US appears to be the imaging procedure of choice because the examination is sensitive for evaluating lesions' edema and cystic components, provides precise measurement of tumor size, and is inexpensive. Degeneration US signs were classified in stage I (an echolucent rim in the periphery of the lesion), stage IIa (lesion with large cystic spaces), stage IIb (tiny cystic spaces) and stage III (absorption of the cystic component or stable cystic remnants).
DOI: 10.1089/cbr.2005.20.215
PubMed: 15869458
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.</title><author><name sortKey="Limouris, Georgios Spyridon" uniqKey="Limouris G">Georgios Spyridon Limouris</name><affiliation wicri:level="1"><nlm:affiliation>Nuclear Medicine Division, Department of Radiology, Aretaieion Hospital, University of Athens, 115028 Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Nuclear Medicine Division, Department of Radiology, Aretaieion Hospital, University of Athens, 115028 Athens</wicri:regionArea></affiliation></author><author><name sortKey="Dimitropoulos, Nikolaos" uniqKey="Dimitropoulos N">Nikolaos Dimitropoulos</name></author><author><name sortKey="Kontogeorgakos, Dimitrios" uniqKey="Kontogeorgakos D">Dimitrios Kontogeorgakos</name></author><author><name sortKey="Papanikolos, Georgios" uniqKey="Papanikolos G">Georgios Papanikolos</name></author><author><name sortKey="Koutoulidis, Vassilios" uniqKey="Koutoulidis V">Vassilios Koutoulidis</name></author><author><name sortKey="Hatzioannou, Achilleas" uniqKey="Hatzioannou A">Achilleas Hatzioannou</name></author><author><name sortKey="Mourikis, Dimitrios" uniqKey="Mourikis D">Dimitrios Mourikis</name></author><author><name sortKey="Lyra, Maria" uniqKey="Lyra M">Maria Lyra</name></author><author><name sortKey="Dimitriou, Panagiotis" uniqKey="Dimitriou P">Panagiotis Dimitriou</name></author><author><name sortKey="Stravaka, Anastasia" uniqKey="Stravaka A">Anastasia Stravaka</name></author><author><name sortKey="Vlahos, Lambros" uniqKey="Vlahos L">Lambros Vlahos</name></author></titleStmt><publicationStmt><date when="2005">2005</date><idno type="doi">10.1089/cbr.2005.20.215</idno><idno type="RBID">pubmed:15869458</idno><idno type="pmid">15869458</idno><idno type="wicri:Area/Main/Corpus">002F11</idno><idno type="wicri:Area/Main/Curation">002F11</idno><idno type="wicri:Area/Main/Exploration">002D79</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>DNA (metabolism)</term><term>Female</term><term>Humans</term><term>Indium (pharmacology)</term><term>Indium Radioisotopes (pharmacology)</term><term>Liver (pathology)</term><term>Liver Neoplasms (secondary)</term><term>Liver Neoplasms (therapy)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Microscopy, Electron</term><term>Middle Aged</term><term>Neoplasm Metastasis (pathology)</term><term>Neoplasms (pathology)</term><term>Neuroendocrine Tumors (radiotherapy)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (pharmacology)</term><term>Pentetic Acid (analogs & derivatives)</term><term>Pentetic Acid (pharmacology)</term><term>Radionuclide Imaging</term><term>Tomography, X-Ray Computed</term><term>Ultrasonics</term><term>Ultrasonography</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Indium</term><term>Indium Radioisotopes</term><term>Octreotide</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term><term>Neoplasm Metastasis</term><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Microscopy, Electron</term><term>Middle Aged</term><term>Radionuclide Imaging</term><term>Tomography, X-Ray Computed</term><term>Ultrasonics</term><term>Ultrasonography</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Thirteen (13) patients with liver neuroendocrine carcinomas metastases, positive for somatostatin receptors, confirmed by scintigraphy were infused with 4070-7030 MBq per session of In-111-octreotide after selective hepatic catheterization, exploiting the catastrophic activity of Indium Auger and Internal Conversion electron emission on cell DNA. Evaluation of the treatment was assessed by ultrasonography (US) as well as by computed tomography and/or magnetic resonance imaging scans. US appears to be the imaging procedure of choice because the examination is sensitive for evaluating lesions' edema and cystic components, provides precise measurement of tumor size, and is inexpensive. Degeneration US signs were classified in stage I (an echolucent rim in the periphery of the lesion), stage IIa (lesion with large cystic spaces), stage IIb (tiny cystic spaces) and stage III (absorption of the cystic component or stable cystic remnants).</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15869458</PMID><DateCreated><Year>2005</Year><Month>05</Month><Day>04</Day></DateCreated><DateCompleted><Year>2005</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1084-9785</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cancer biotherapy & radiopharmaceuticals</Title><ISOAbbreviation>Cancer Biother. Radiopharm.</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.</ArticleTitle><Pagination><MedlinePgn>215-7</MedlinePgn></Pagination><Abstract><AbstractText>Thirteen (13) patients with liver neuroendocrine carcinomas metastases, positive for somatostatin receptors, confirmed by scintigraphy were infused with 4070-7030 MBq per session of In-111-octreotide after selective hepatic catheterization, exploiting the catastrophic activity of Indium Auger and Internal Conversion electron emission on cell DNA. Evaluation of the treatment was assessed by ultrasonography (US) as well as by computed tomography and/or magnetic resonance imaging scans. US appears to be the imaging procedure of choice because the examination is sensitive for evaluating lesions' edema and cystic components, provides precise measurement of tumor size, and is inexpensive. Degeneration US signs were classified in stage I (an echolucent rim in the periphery of the lesion), stage IIa (lesion with large cystic spaces), stage IIb (tiny cystic spaces) and stage III (absorption of the cystic component or stable cystic remnants).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Limouris</LastName><ForeName>Georgios Spyridon</ForeName><Initials>GS</Initials><Affiliation>Nuclear Medicine Division, Department of Radiology, Aretaieion Hospital, University of Athens, 115028 Athens, Greece.</Affiliation></Author><Author ValidYN="Y"><LastName>Dimitropoulos</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kontogeorgakos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Papanikolos</LastName><ForeName>Georgios</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Koutoulidis</LastName><ForeName>Vassilios</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Hatzioannou</LastName><ForeName>Achilleas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mourikis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lyra</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dimitriou</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Stravaka</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vlahos</LastName><ForeName>Lambros</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Biother Radiopharm</MedlineTA><NlmUniqueID>9605408</NlmUniqueID><ISSNLinking>1084-9785</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>111In-octreotide, DTPA(0)-</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>045A6V3VFX</RegistryNumber><NameOfSubstance>Indium</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance>DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">DNA</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium</DescriptorName><QualifierName MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liver</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">secondary</QualifierName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Metastasis</DescriptorName><QualifierName MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Ultrasonics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2005.20.215</ArticleId><ArticleId IdType="pubmed">15869458</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15869458
|texte= Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15869458" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |